找到相关结果： 962

ASH 2016: Syk Inhibitor HMPL-523 Anti-tumor Activity in vitro and in vivo

HMPL-523, a Novel SYK Inhibitor, Showed Anti-tumor Activities in Vitro and in Vivo Na Yang, Wei Deng, Qiaoling Sun, Junqing Liang, Linfang Wang, Shiming Fan, Renxiang Tang, Ying Yu, Junen Sun, Feng Zhou, Guangxiu Dai, Yongxin Ren, Weiguo Qing and We

演示文稿, 科学出版物 | 2016-12-05

WCLC 2016: Epitinib in EGFRm+ NSCLC Patients with Brain Metastasis

A Phase Ib study of Epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRm+) NSCLC patients with brain metastasis Qing Zhou1, Bin Gan1, Qunying Hong2, Mengzhao Wang3, XiaoQing Liu4, Liwei Yuan5, Ye Hua5, Hongcan Ren5, Weiguo Su5,

公告及新闻稿, 监管通知 | 2016-11-30

Exercise of Share Options by a Person Discharging Managerial Responsibilities

London: Wednesday, November 30, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Weiguo Su, Executive Vice President and Chief Scientific Officer (being a Person Discharging Managerial Respons

公告及新闻稿, 监管通知 | 2016-11-30

Total Voting Rights

London: Wednesday, November 30, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2016, the issued share capital of Chi-Med consisted of 60,703,323 or

公告及新闻稿, 监管通知 | 2016-11-23

Director’s Share Dealing

London: Wednesday, November 23, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-11-23

Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)

Press Release London: Wednesday, November 23, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that results from two non-small cell lung cancer (“NSCLC”) clinical studies will be presented at WCLC in Vienn

演示文稿, 科学出版物 | 2016-11-14

ACR 2016: Phase I Dose Escalating Study of HMPL-523 in Australian Male Healthy Subjects

A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HMPL-523 in Australian Male Healthy Subjects Background: S

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-11-14

Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting

Press Release London: Monday, November 14, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokineti

公告及新闻稿, 监管通知 | 2016-11-01

Director's Share Dealing

London: Tuesday, November 1, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the �

公告及新闻稿, 其他业务, 新闻稿 | 2016-10-31

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

Shanghai agreement triggers a one-time gain to Chi-Med of US$38.2 million in Q4 2016 Shanghai factory relocation complete: now operational with three-fold increase in capacity Cash from Chi-Med Commercial Platform supports developmen

公告及新闻稿, 监管通知 | 2016-10-12

Director's Share Dealing

London: Wednesday, October 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, has sold 15,000 ordinary shares of US$1.00 each in Chi-Med (

公告及新闻稿, 监管通知 | 2016-08-09

Director's Share Dealing

London: Tuesday, August 9, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US

公告及新闻稿, 集团 | 2016-08-02

Change of Non-executive Directors

London: Tuesday, August 2, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who ha

公告及新闻稿, 集团 | 2016-08-02

Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to Chi‑Med of $0.5 million (H1 2015: $15.9m), reflecting a sharp increase in clinical investment. Innovation Platform – Seven drug candidates in 25

公告及新闻稿, 肿瘤学 / 免疫学 | 2016-08-01

为加快沃利替尼全球研发项目，和黄医药与阿斯利康签署共同开发补充协议

1 个附件

首个以c-Met异常乳头状肾细胞癌（“PRCC”）为适应症的全球III期临床试验将于近期启动 2016年8月1日：和黄医药和阿斯利康今日宣布在2011年双方就沃利替尼达成的合作协议的基础上签

查看公告 (PDF)

公告及新闻稿, 集团 | 2016-07-05

Chi-Med to Announce 2016 Half-Year Financial Results

London: Tuesday, July 5, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer Time (BST). An a

公告及新闻稿, 监管通知 | 2016-06-29

Blocklisting Six Monthly Return

公告及新闻稿, 肿瘤学 / 免疫学 | 2016-06-20

和黄医药启动沃利替尼以EGFR突变非小细胞肺癌为适应症的全球II期临床试验

1 个附件

扩展的非小细胞肺癌II期临床试验启动，阿斯利康向和黄医药支付1000万美元里程金此研究的开展是基于沃利替尼早先与Tagrisso或Iressa联合用药治疗c-Met扩增非小细胞肺癌的初始小型II期

查看公告 (PDF)

公告及新闻稿, 监管通知 | 2016-06-15

Block Admission

London: Wednesday, June 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,000,000 ordinary shares, par value of U

演示文稿, 科学出版物 | 2016-06-03

ASCO 2016: Safety profile and preliminary clinical efficacy of epitinib in EGFRm+ NSCLC

The safety profile of a selective EGFR TKI epitinib (HMPL-813) in patients with advanced solid tumors and preliminary clinical efficacy in EGFRm+ NSCLC patients with brain metastasis Authors: Qing Zhou, Bin Gan, Liwei Yuan, Ye Hua, Yi-Long Wu Ba

演示文稿, 科学出版物 | 2016-06-03

ASCO 2016: Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer

Authors: Jin-Ji Yang, Liu Yang, Andrew Farnsworth, Amir Handzel, Tanya Coleman, Shethah Morgan, Yi-Long Wu Background: Savolitinib (AZD6094, volitinib, HMPL-504) is a potent & selective small molecule MET inhibitor. In preclinical models the c

公告及新闻稿, 监管通知 | 2016-05-31

Total Voting Rights

London: Tuesday, May 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2016, the issued share capital of Chi-Med consisted of 60,649,342 ordinary sha

公告及新闻稿, 肿瘤学 / 免疫学 | 2016-05-13

和黄医药完成呋喹替尼以结直肠癌为适应症的III期临床试验的患者入组工作，共招募416名患者

1 个附件

2016年5月13日：和黄医药今日宣布呋喹替尼（HMPL-013）以结直肠癌为适应症的III期临床试验“FRESCO”顺利完成患者入组工作。2012年，中国新发结直肠癌病例约为39万例，呋喹替尼的这项关键性I

查看公告 (PDF)

新闻稿, 集团 | 2016-05-04

Chi-Med to Participate in Two Healthcare Investor Conferences in May

London—May 2, 2016—Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announced that Chief Executive Officer Christian Hogg will present a corporate overview at two healthcare investor conferences in May. Conference Details: E

公告及新闻稿, 监管通知 | 2016-04-29

Total Voting Rights

London: Friday, April 29, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 29, 2016, the issued share capital of Chi-Med consisted of 60,639,926 ordinary

公告及新闻稿, 监管通知 | 2016-04-27

Results of Annual General Meeting

London: Wednesday, April 27, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and the special resolution put to its Annual General Meeting ("AGM") held on April 27, 2016 were duly pas

演示文稿, 科学出版物 | 2016-04-16

AACR 2016: Activity of Savolitinib against MET Ex14 mutations and resistance to METi through decoupling from MYC expression

Abstract (please download the poster for full details) Authors: Evan Barry, Ryan Henry, Alexandra Borodovsky, Elizabeth Maloney, Brendon Ladd, Melanie Frigault, Michael Zinda, Edwin Clark, Alwin Schuller and Celina D’Cruz Alterations in the

公告及新闻稿, 集团 | 2016-04-13

Hutchison China MediTech Limited Announces Exercise of Overallotment Option

London: Wednesday, April 13, 2016: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the “Offering”) have

公告及新闻稿, 肿瘤学 / 免疫学 | 2016-04-12

Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689

London: Tuesday, April 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the first-in-human (“FIH”) Phase I cli

公告及新闻稿, 监管通知 | 2016-03-31

Total Voting Rights

London: Thursday, March 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2016, the issued share capital of Chi-Med consisted of 60,283,118 ordinary

公告及新闻稿, 监管通知 | 2016-03-29

Director's Shareholding

London: Tuesday, March 29, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM / Nasdaq: HCM) received notification on March 25, 2016 that Mr Christian Hogg, Executive Director and Chief Executive Officer, has purchased 36,600 American Deposi

公告及新闻稿, 监管通知 | 2016-03-23

Holding(s) in Company

For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying is

公告及新闻稿, 新闻稿, 集团 | 2016-03-22

Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT

公告及新闻稿, 监管通知 | 2016-03-21

Director's Shareholding

London: Monday, March 21, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM / Nasdaq: HCM) received notification on 18 March 2016 that Ms Edith Shih, Non-executive Director, has purchased 40,741 American Depositary Shares ("ADSs", each represen

公告及新闻稿, 肿瘤学 / 免疫学 | 2016-03-21

Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients

London: Monday, March 21, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of s

公告及新闻稿, 集团 | 2016-03-18

Final Prospectus

公告及新闻稿, 集团 | 2016-03-17

Pricing of U.S. Public Offering of ADSs

公告及新闻稿, 新闻报道, 集团 | 2016-03-17

Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs

Press Release London: Wednesday, March 16, 2016: Hutchison China MediTech Limited ("Chi Med") (AIM: HCM) announces the pricing of its U.S. public offering of American depositary shares (“ADSs”) (the “Offering”), raising gross proceeds of app

公告及新闻稿, 集团 | 2016-03-15

2015 Annual Report and Notice of Annual General Meeting

London: Tuesday, March 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) today announces that its 2015 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The

公告及新闻稿, 集团 | 2016-03-07

Repeat of Announcement of Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

公告及新闻稿, 集团 | 2016-03-04

Hutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs

Press Release London: Friday, 4 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares in the f

公告及新闻稿, 集团 | 2016-03-04

Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-03-02

和黄医药启动索凡替尼以甲状腺癌为适应症的II期临床研究

1 个附件

2016年3月2日：和黄医药今日宣布正式启动索凡替尼（HMPL-012）以局部晚期或放射性碘难治性转移分化的甲状腺癌（DTC）或甲状腺髓样癌（MTC）为适应症在中国开展的一项开放式II期临床研究，

下载新闻稿 (PDF)

公告及新闻稿, 集团 | 2016-03-01

Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

公告及新闻稿, 集团 | 2016-03-01

Final Results for the year ended 31 December 2015

Record profit from operations at both Group and Commercial Platform levels Excellent progress on all lead drug candidates – five out of five positive Phase Ib/II outcomes in 2015 Seven drug candidates – 19 active clinical trials – 3 Phase III

公告及新闻稿, 集团 | 2016-02-11

Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

公告及新闻稿, 监管通知 | 2016-01-29

Notice of Announcement of 2015 Final Results

London: Friday, 29 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) will be announcing its final results for the year ended 31 December 2015 on Tuesday, 1 March 2016. An analyst presentation will be held at 9:00 am on the

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-01-15

和黄医药在澳大利亚启动HMPL-523以血液肿瘤为适应症的I期临床试验

1 个附件

2016年1月15日：和黄医药今日宣布在澳大利亚启动HMPL-523以恶性血液肿瘤为适应症的I期临床试验。HMPL-523是针对B细胞受体信号通路中的酪氨酸激酶Syk的新型高选择性小分子抑制剂。此次研究的

下载新闻稿 (PDF)

公告及新闻稿, 监管通知 | 2015-12-29

Blocklisting Six Monthly Return

London: Tuesday, 29 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutc

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2015-12-18

和黄医药启动索凡替尼以神经内分泌瘤为适应症的III期临床研究

1 个附件

2015年12月18日：和黄医药今日宣布正式启动索凡替尼（HMPL-012）以非胰腺神经内分泌瘤为适应症的中国III期临床研究（SANET-ep）。此次研究的受试者均为非胰腺神经内分泌瘤患者，包括原发于�

下载新闻稿 (PDF)

1 2 3 4 5 6 7 8 9 10 11 12 13

15 16 17 18 19 20